专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004110430A1 USE OF SUBSTITUTED CHROMANS OR THIOCROMANS FOR THE TREATMENT OF FGD 审中-公开
标题翻译：使用替代的色素或三氧化物来处理烟气脱硫
公开(公告)号：WO2004110430A1
公开(公告)日：2004-12-23
申请号：PCT/SE2004/000963
申请日：2004-06-16
申请人： ASTRAZENECA AB , THORBERG, Seth-Olov
发明人： THORBERG, Seth-Olov
IPC分类号： A61K31/353
CPC分类号： A61K31/382 , A61K31/353
摘要： The present invention relates to the use of substituted 3-amino chromans or thiocromans as well as enantiomers and salts thereof for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.
摘要翻译：本发明涉及取代的3-氨基苯并二氢吡喃酮或噻托溴铵及其对映异构体和盐在治疗功能性消化道疾病如功能性消化不良中的用途。

2. 发明申请

WO2004110447A1 USE OF TETRAHYDRONAPHTALENE DERIVATIVES FOR TREATMENT OF GI DISORDERS 审中-公开
标题翻译：四氢乙烯衍生物用于治疗胃肠疾病的用途
公开(公告)号：WO2004110447A1
公开(公告)日：2004-12-23
申请号：PCT/SE2004/000962
申请日：2004-06-16
申请人： ASTRAZENECA AB , THORBERG, Seth-Olov
发明人： THORBERG, Seth-Olov
IPC分类号： A61K31/451
CPC分类号： A61K31/451 , A61K31/495 , A61K31/496 , A61K31/5377
摘要： The present invention relates to the use of piperidyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.
摘要翻译：本发明涉及哌啶基或哌嗪基取代的-1,2,3,4-四氢萘衍生物用于治疗功能性消化道疾病如功能性消化不良的用途。

3. 发明申请

WO2004110446A1 USE OF TETRAHYDRONAPHTALENE DERIVATIVES FOR THE TREATMENT OF IBS 审中-公开
标题翻译：用于治疗IBS的四氢吡啶衍生物的用途
公开(公告)号：WO2004110446A1
公开(公告)日：2004-12-23
申请号：PCT/SE2004/000961
申请日：2004-06-16
申请人： ASTRAZENECA AB , THORBERG, Seth-Olov
发明人： THORBERG, Seth-Olov
IPC分类号： A61K31/451
CPC分类号： A61K31/451 , A61K31/495 , A61K31/496
摘要： The present invention relates to the use of piperidyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives for the treatment of irritable bowel syndrome (IBS).
摘要翻译：本发明涉及哌啶基或哌嗪基取代-1,2,3,4-四氢萘衍生物用于治疗肠易激综合征（IBS）的用途。

4. 发明申请

WO2004110429A1 USE OF SUBSTITUTED CHROMANS OR THIOCROMANS FOR THE TREATMENT OF IBS 审中-公开
标题翻译：使用替代的染色体或三聚体来治疗IBS
公开(公告)号：WO2004110429A1
公开(公告)日：2004-12-23
申请号：PCT/SE2004/000960
申请日：2004-06-16
申请人： ASTRAZENECA AB , THORBERG, Seth-Olov
发明人： THORBERG, Seth-Olov
IPC分类号： A61K31/353
CPC分类号： A61K31/282 , A61K31/353
摘要： The present invention relates to the use of substituted 3-amino chromans or thiocromans as well as enantiomers and salts thereof for the treatment of irritable bowel syndrome (IBS).
摘要翻译：本发明涉及取代的3-氨基苯并二氢吡喃酮或噻托溴铵及其对映异构体和盐在治疗肠易激综合征（IBS）中的用途。

5. 发明授权

EP0888319B1 SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES 失效
标题翻译：取代1,2,3,4-四氢
公开(公告)号：EP0888319B1
公开(公告)日：2003-01-29
申请号：EP97914727.9
申请日：1997-03-20
申请人： AstraZeneca AB
发明人： BERG, Stefan , FLORVALL, Lennart , ROSS, Svante , THORBERG, Seth-Olov
IPC分类号： C07D295/135 , C07D295/155 , C07D211/26 , C07D211/34 , A61K31/495 , A61K31/445
CPC分类号： C07D295/096 , A61K31/496 , C07C2601/16 , C07C2602/10 , C07D211/26 , C07D211/34 , C07D241/00 , C07D295/135 , C07D295/215
摘要： New piperidinyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives having formula (I) wherein X is N or CH; Y is NR2CH2, CH2-NR2, NR2-CO, CO-NR2 or NR2SO2; R1 is H, C1-C6 alkyl or C3-C6 cycloalkyl; R3 is C1-C6 alkyl, C3-C6 cycloalkyl or (CH2)n-aryl, where aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; as (R)-enantiomer, (S)-enantiomer or a racemate in the form of the free base or a pharmaceutically acceptable salt or hydrate thereof; a pharmaceutical formulation containing the compounds, use of the compounds in the treatment of 5-hydroxytryptamine mediated disorders, processes for the preparation of the compounds and intermediates for the preparation of the compounds.

6. 发明公开

EP1025096A1 SUBSTITUTED CHROMAN DERIVATIVES 有权
标题翻译：取代的色素衍生物
公开(公告)号：EP1025096A1
公开(公告)日：2000-08-09
申请号：EP98944378.3
申请日：1998-09-09
申请人： AstraZeneca AB
发明人： BERG, Stefan , LINDERBERG, Mats , ROSS, Svante , THORBERG, Seth-Olov , ULFF, Bengt
IPC分类号： C07D311/58 , A61K31/495 , A61K31/535
CPC分类号： C07D311/58
摘要： The present invention relates to new piperidinyl- or piperazinyl-substituted-3,4-dihydro-2H-1-benzopyran derivatives having formula (I) wherein X is N or CH; Y is NR2CH2, CH2NR2, NR2CO, CONR2 or NR2SO2 wherein R2 is H or C1-C6 alkyl; R1 is H, C1-C6 alkyl or C3-C6 cycloalkyl; R3 is C1-C6 alkyl, C3-C6 cycloalkyl or (CH2)n-aryl, wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; R9 is C1-C6 alkyl, C3-C6 cycloalkyl, OCF3, OCHF2, OCH2F, halogen, CONR6R7, CN, CF3, OH, C1-C6 alkoxy, NR6R7, SO3CH3, SO3CF3, SO2NR6R7, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C1-C6 alkyl; or COR8; wherein R6, R7 and R8 are as defined above, as (R)-enantiomers, (S)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.
摘要翻译：本发明涉及具有式（I）的新的哌啶基或哌嗪基取代的-3,4-二氢-2H-1-苯并吡喃衍生物，其中X是N或CH; Y是NR 2 CH 2，CH 2 NR 2，NR 2 CO，CONR 2或NR 2 SO 2，其中R 2是H或C 1 -C 6烷基; R1是H，C1-C6烷基或C3-C6环烷基; R 3是C 1 -C 6烷基，C 3 -C 6环烷基或（CH 2）n - 芳基，其中芳基是苯基或含有一个或两个选自N，O和S的杂原子并且可以是单取代或二取代的杂芳族环; n是0-4; R9是C1-C6烷基，C3-C6环烷基，OCF3，OCHF2，OCH2F，卤素，CONR6R7，CN，CF3，OH，C1-C6烷氧基，NR6R7，SO3CH3，SO3CF3，SO2NR6R7，未取代或取代的杂环或杂芳族环一个或两个选自N和O的杂原子，其中取代基为C 1 -C 6烷基; 或COR8; （R） - 对映异构体，（S） - 对映异构体或外消旋体或其药学上可接受的盐或溶剂合物形式，其制备方法，含有所述化合物的药物组合物，其中R 6，R 7和R 8如上所定义，治疗活性化合物以及所述活性化合物在治疗中的用途。

7. 发明授权

EP1014985B1 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST 有权
标题翻译：组合5-HT回收抑制剂和H5-HT 1B拮抗剂或部分激动剂
公开(公告)号：EP1014985B1
公开(公告)日：2003-05-21
申请号：EP98944375.9
申请日：1998-09-09
申请人： AstraZeneca AB
发明人： BERG, Stefan , ROSS, Svante , THORBERG, Seth-Olov
IPC分类号： A61K31/495 , A61K31/535 , A61P25/24
CPC分类号： A61K31/495 , A61K31/535 , A61K31/55 , A61K31/445 , A61K31/34 , A61K31/135 , A61K2300/00
摘要： The invention relates to a combination of a first component (a) which is a 5-HT reuptake inhibitor and a second component (b) which is selective h5-HT1B antagonist or partial agonist having formula (I) wherein X is CH2, O; Y is CONH, NHCO; R1 is H, C1-C6 alkyl, C3-C6 cycloalkyl; R2 is H, C1-C6 alkyl, C1-C6 alkoxy, halogen; R3 is (1), (2), (3), CF3; R4 and R5 independently are H, or C1-C4 alkyl, as racemate, R-enantiomer or S-enantiomer, and said components (a) and (b) being in the form of free bases, solvents or pharmaceutically acceptable salts thereof, the preparation thereof, pharmaceutical formulations containing said combinations, use of and method of treatment of affective disorders such as depression, anxiety and OCD with said combination as well as kit containing said combination.

8. 发明公开

EP1133292A1 A NEW PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：新的药物组合物
公开(公告)号：EP1133292A1
公开(公告)日：2001-09-19
申请号：EP99963749.9
申请日：1999-11-23
申请人： AstraZeneca AB
发明人： ROSS, Svante , THORBERG, Seth-Olov
IPC分类号： A61K31/35
CPC分类号： A61K31/35 , A61K31/535 , A61K31/15 , A61K2300/00
摘要： The invention relates to a composition comprising a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide in the form of the free base, pharmaceutically acceptable salts and/or solvates thereof, and a second component (b) which is a monoamine oxidase (MAO) inhibitor in the form of the free base, pharmaceutically acceptable salts and/or solvates thereof, the preparation thereof, pharmaceutical formulations containing said composition, a kit containing said composition, use of and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition.

9. 发明授权

EP1014986B1 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST 有权
标题翻译：单胺氧化酶抑制剂和H5-HT 1 BETA拮抗剂或PARTIELLAGONIST含氮化合物
公开(公告)号：EP1014986B1
公开(公告)日：2004-07-14
申请号：EP98944376.7
申请日：1998-09-09
申请人： AstraZeneca AB
发明人： BERG, Stefan , ROSS, Svante , THORBERG, Seth-Olov
IPC分类号： A61K31/495 , A61K31/535
CPC分类号： A61K31/495 , A61K31/535 , A61K31/15 , A61K2300/00
摘要： The invention relates to a combination of a first component (a) which is a monoamine oxidase inhibitor and a second component (b) which is selective h5-HT1B antagonist or partial agonist having formula (I) wherein X is CH2, O; Y is CONH, NHCO; R1 is H, C1-C6 alkyl, C3-C6 cycloalkyl; R2 is H, C1-C6 alkyl, C1-C6 alkoxy, halogen; R3 is formula (II); R4 and R5 independently are H or C1-C4 alkyl, as racemate, R-enantiomer or S-enantiomer, and said components (a) and (b) being i n the form of free bases, solvates or pharmceutically acceptable salts thereof, the preparation thereof, pharmaceutical formulations containing said combinations, use of and method of treatment of affective disorders such as depression, anxiety and OCD with said combination as well as a kit containing said combination.

10. 发明授权

EP0822813B1 A COMBINATION OF A 5-HT UPTAKE INHIBITOR WITH A SELECTIVE 5-HT 1A ANTAGONIST 失效
标题翻译：组合的5-HT UPTAKEINIBITORS与选择性5-HT1A拮抗剂
公开(公告)号：EP0822813B1
公开(公告)日：2002-04-24
申请号：EP96912370.2
申请日：1996-04-23
申请人： AstraZeneca AB
发明人： EVENDEN, John , THORBERG, Seth-Olov
IPC分类号： A61K31/353 , A61K31/40 , A61P25/24
CPC分类号： A61K31/35 , A61K31/445 , A61K31/55 , A61K31/34 , A61K31/135 , A61K2300/00
摘要： The invention relates to a combination of a first component (a) which is a 5-HT reuptake inhibitor and a second component (b) which is selective 5-HT1A antagonist of general formula (I), wherein R1 is n-propyl or cyclobutyl; R2 is isopropyl, tertiary butyl, cyclobutyl, cyclopentyl or cyclohexyl; R3 is hydrogen; R4 is hydrogen or methyl; as (R)-enantiomer in the form of free base or pharmaceutically acceptable salts thereof, the preparation thereof, pharmaceutical formulations containing said combination, use of and method of treatment of affective disorders such as depression, anxiety and OCD with said combination as well as a kit containing said combination.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式